Join Pharvaris for a virtual investor event featuring Michael Manning, M.D. (Allergy, Asthma & Immunology, LTD) and Raffi Tachdjian, M.D., MPH (David Geffen School of Medicine at the University of California, Los Angeles), who will join company management to discuss the unmet medical need and current treatment landscape for hereditary angioedema (HAE) attacks and other bradykinin-mediated diseases.

The event will focus on the company’s clinical development programs for deucrictibant, a novel, potent, oral small-molecule bradykinin B2 receptor antagonist, for both the prophylactic and on-demand treatment of HAE attacks.

Following the KOL presentations, Pharvaris senior management the unmet need in both the prophylactic and on-demand treatment of HAE attacks, the potential of deucrictibant to address to needs, and the current HAE market dynamics.

A live question and answer session will follow the formal presentations.